(a) The Secretary shall establish guidelines for the co-prescribing of opioid overdose reversal drugs that are applicable to all licensed health care providers in the State who are authorized by law to prescribe a monitored prescription drug, as defined in § 21-2A-01 of this article.
(b) The guidelines established under subsection (a) of this section shall address the co-prescribing of opioid overdose reversal drugs for patients who are:
(1) At an elevated risk of overdose; and
(2) (i) Receiving opioid therapy for chronic pain;
(ii) Receiving a prescription for benzodiazepines; or
(iii) Being treated for opioid use disorders.